Body-mass index, cancer, and implications for screening

Clarisse Eveno; Yann Parc; Alexis Laurent; Michel Ducreux; Marc Pocard

doi:10.1016/S1470-2045(15)70029-X

Body-mass index, cancer, and implications for screening

Clarisse Eveno, Yann Parc, Alexis Laurent, Michel Ducreux, Marc Pocard

Research output: Contribution to journal › Letter › peer-review

4 Citations (Scopus)

Original language	English
Pages (from-to)	e102-e103
Journal	The Lancet Oncology
Volume	16
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(15)70029-X
Publication status	Published - 1 Mar 2015

Access to Document

10.1016/S1470-2045(15)70029-X

Cite this

@article{051b2fcaba6d497cb0f73c58f2492572,

title = "Body-mass index, cancer, and implications for screening",

author = "Clarisse Eveno and Yann Parc and Alexis Laurent and Michel Ducreux and Marc Pocard",

note = "Funding Information: YP declares funding from Eumedica, Olympus, Sanofi, and Brothier, outside the scope of this work. The other authors declare no competing interests. The analysis of data from the COINCIDE database presented here was done by Alexandre Templier and Alexandre Civet (Quinten, Paris, France), paid for by industrial funding from Roche France. Roche France did not have access to the COINCIDE database, and were not involved in the analysis or development of the question addressed here.",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/S1470-2045(15)70029-X",

language = "English",

volume = "16",

pages = "e102--e103",

journal = "The Lancet Oncology",

issn = "1470-2045",

number = "3",

}

TY - JOUR

T1 - Body-mass index, cancer, and implications for screening

AU - Eveno, Clarisse

AU - Parc, Yann

AU - Laurent, Alexis

AU - Ducreux, Michel

AU - Pocard, Marc

N1 - Funding Information: YP declares funding from Eumedica, Olympus, Sanofi, and Brothier, outside the scope of this work. The other authors declare no competing interests. The analysis of data from the COINCIDE database presented here was done by Alexandre Templier and Alexandre Civet (Quinten, Paris, France), paid for by industrial funding from Roche France. Roche France did not have access to the COINCIDE database, and were not involved in the analysis or development of the question addressed here.

PY - 2015/3/1

Y1 - 2015/3/1

UR - http://www.scopus.com/inward/record.url?scp=84924856034&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)70029-X

DO - 10.1016/S1470-2045(15)70029-X

M3 - Letter

C2 - 25752554

AN - SCOPUS:84924856034

SN - 1470-2045

VL - 16

SP - e102-e103

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 3

ER -

Body-mass index, cancer, and implications for screening

Access to Document

Other files and links

Cite this